Cladribine Low Dose

Phase 3

MERCK (MRK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Generalized Myasthenia Gravis

View Full Landscape

Drug Information

Target Indication

Generalized Myasthenia Gravis

Clinical Trial

NCT06463587

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Movectro

View on EMA

EMA8/22/2017

Mavenclad

Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.

View on EMA

EMA4/14/2004

Litak

Litak is indicated for the treatment of hairy-cell leukaemia.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Vericiguat tabletPhase 3

Heart Failure

Pegylated interferon alfa-2b (SCH 54031)Phase 3

Hepatitis C, Chronic

ElbasvirPhase 3

Hepatitis C

V260Phase 3

Rotavirus Gastroenteritis

MK-8591APhase 3

HIV-1 Infection

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts